Inhibiting mTOR was found to reduce the viability of CD133+ pancreatic cancer cells [132] but also causes an increase in CD133+ gastrointestinal cancer cells [131]; in this context, however, HIF-1α induction down-regulated CD133 expression. This evidence concerns the gene PROM1 and familial pancreatic carcinoma.